A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
The purpose of this Phase II Study is to determine the response rate of NFI patients with plexiform neurofibromas treated with Cabozantinib therapy using MRI scans.
This phase II open label study will evaluate adolescents and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with cabozantinib (XL184).
- IRB Number: 1305011412 (1305005374) (CABOZANTINIB)
- Research Study Identifier: TX3396
- Principal Investigator: Michael Ferguson, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required